Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC.

被引：0
|
作者：
Janne, Pasi A.
Yu, Helena Alexandra
Johnson, Melissa Lynne
Steuer, Conor Ernst
Vigliotti, Michele
Iacobucci, Corinne
Chen, Shuquan
Yu, Channing
Sellami, Dalila B.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] Daiichi Sankyo Inc, Basking Ridge, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9010
引用
收藏
页数：1
相关论文
共 35 条
  • [1] Preliminary Phase 1 Results of U3-1402-A Novel HER3-Targeted Antibody-Drug Conjugate-in EGFR TKI-Resistant, EGFR-Mutant NSCLC
    Yu, H.
    Johnson, M.
    Steuer, C.
    Vigliotti, M.
    Chen, S.
    Kamai, Y.
    Yu, C.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S336 - S337
  • [2] Updated efficacy and safety of patritumab deruxtecan (HER3-DXd; U3-1402), a HER3 directed antibody drug conjugate, in EGFRm NSCLC
    Hayashi, Hidetoshi
    Yu, Helena A.
    Baik, Christina
    Gold, Kathryn
    Johnson, Melissa L.
    Koczywas, Marianna
    Murakami, Haruyasu
    Nishio, Makoto
    Steuer, Conor
    Su, Wu-Chou
    Yang, James C. H.
    Karam, Samer
    Qui, Zhenhao
    Qiu, Yang
    Chen, Shuquan
    Yu, Channing
    Janne, Pasi A.
    ANNALS OF ONCOLOGY, 2021, 32 : S318 - S318
  • [3] EGFR inhibition enhances the cellular uptake and antitumor activity of the novel HER3 antibody drug conjugate U3-1402
    Haikala, Heidi M.
    Kohler, Jens
    Lopez, Timothy
    Eser, Pinar
    Xu, Man
    Yu, Channing
    Shiose, Yoshinobu
    Qiu, Yang
    Gokhale, Prafulla
    Janne, Pasi A.
    CANCER RESEARCH, 2020, 80 (16)
  • [4] Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
    Yu, H. A.
    Baik, C. S.
    Gold, K.
    Hayashi, H.
    Johnson, M.
    Koczywas, M.
    Murakami, H.
    Nishio, M.
    Steuer, C.
    Su, W-C.
    Yang, J.
    Karam, S.
    Qi, Z.
    Qiu, Y.
    Chen, S.
    Yu, C.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1189 - S1190
  • [5] Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
    Yu, H.
    Baik, C.
    Gold, K.
    Hayashi, H.
    Johnson, M.
    Koczywas, M.
    Murakami, H.
    Nishio, M.
    Steuer, C.
    Su, W.
    Yang, J. C.
    Karam, S.
    Qi, Z.
    Qiu, Y.
    Chen, S.
    Yu, C.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S107 - S107
  • [6] Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC
    Janne, P.
    Yu, H.
    Johnson, M.
    Steuer, C.
    Vigliotti, M.
    Shipitofsky, N.
    Guevara, F. M.
    Chen, S.
    Yu, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S815 - S816
  • [7] Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC
    Janne, P.
    Yu, H.
    Vigliotti, M.
    Shipitofsky, N.
    Singh, J.
    Guevara, F.
    Yu, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2290 - S2290
  • [8] Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC
    Janne, Pasi A.
    Yu, Helena Alexandra
    Johnson, Melissa Lynne
    Vigliotti, Michele
    Shipitofsky, Nicole
    Guevara, Ferdinand Morales
    Chen, Shuquan
    Yu, Channing
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] EGFR inhibitor upregulates HER3 expression and enhances the efficacy of anti-HER3 antibody drug conjugate U3-1402
    Yonesaka, Kimio
    Tanizaki, Junko
    Maenishi, Osamu
    Kawakami, Hisato
    Tanaka, Kaoru
    Hayashi, Hidetoshi
    Takeda, Masayuki
    Sakai, Kazuko
    Kobayashi, Maki
    Yoshimoto, Ryoto
    Goto, Hiroki
    Funabashi, Masanori
    Hashimoto, Yuuri
    Hirotani, Kenji
    Kagari, Takashi
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    ANNALS OF ONCOLOGY, 2021, 32 : S296 - S296
  • [10] An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC
    Kimio Yonesaka
    Naoki Takegawa
    Satomi Watanabe
    Koji Haratani
    Hisato Kawakami
    Kazuko Sakai
    Yasutaka Chiba
    Naoyuki Maeda
    Takashi Kagari
    Kenji Hirotani
    Kazuto Nishio
    Kazuhiko Nakagawa
    Oncogene, 2019, 38 : 1398 - 1409
1234